Barely Significant
← all excerpts

Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial.

Br J Cancer · 2024 · PMC10803799 · PMID 37996507

Europe PMCDOI
1
hedged sentence
0.0130
closest p · 0.3× alpha
0.0130
boldest claim

The sentences

showed a trendP = 0.013actually significant
23.8 months, P < 0.0001) and showed a trend to improved PFS ( P = 0.013) compared to patients not achieving NED status (Supplementary Fig.

also in 11,799 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.